Risk predictors of underestimation and the need for sentinel node biopsy in patients diagnosed with ductal carcinoma in situ by preoperative needle biopsy

Journal of Surgical Oncology

Volumn 107, Issue 4, 2013, Pages 388-392

  Park, Hyung Seok ^a   Park, Seho ^a   Cho, Junghoon ^a   Park, Ji Min ^a   Kim, Seung Il ^a   Park, Byeong Woo ^a  

^a Yonsei University   (South Korea)

Author keywords

breast neoplasms; ductal carcinoma in situ; noninfiltrating intraductal carcinoma; sentinel lymph node biopsy

Indexed keywords

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER INVASION; CANCER SIZE; ECHOGRAPHY; HUMAN; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; NEEDLE BIOPSY; PALPATION; PRIORITY JOURNAL; SENTINEL LYMPH NODE BIOPSY; TUMOR CALCINOSIS;

ADULT; AGED; AXILLA; BIOPSY, LARGE-CORE NEEDLE; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FACTOR ANALYSIS, STATISTICAL; FEMALE; HUMANS; LOGISTIC MODELS; LYMPH NODES; LYMPHATIC METASTASIS; MAMMOGRAPHY; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PREOPERATIVE PERIOD; RISK ASSESSMENT; RISK FACTORS; SENTINEL LYMPH NODE BIOPSY; TUMOR MARKERS, BIOLOGICAL; ULTRASONOGRAPHY, MAMMARY;

EID: 84874270539     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23273     Document Type: Article

References (23)

1. Lyman GH, Giuliano AE, Somerfield MR, et al.: American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 2005; 23: 7703-7720.
2. Veronesi U, Paganelli G, Viale G, et al.: A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 2003; 349: 546-553.
3. Barranger E, Dubernard G, Fleurence J, et al.: Subjective morbidity and quality of life after sentinel node biopsy and axillary lymph node dissection for breast cancer. J Surg Oncol 2005; 92: 17-22.
4. Crane-Okada R, Wascher RA, Elashoff D, Giuliano AE:, Long-term morbidity of sentinel node biopsy versus complete axillary dissection for unilateral breast cancer. Ann Surg Oncol 2008; 15: 1996-2005.
5. Intra M, Rotmensz N, Veronesi P, et al.: Sentinel node biopsy is not a standard procedure in ductal carcinoma in situ of the breast: The experience of the European institute of oncology on 854 patients in 10 years. Ann Surg 2008; 247: 315-319.
6. Cody HS 3rd:, Sentinel lymph node biopsy for DCIS: Are we approaching consensus ? Ann Surg Oncol 2007; 14: 2179-2181.
7. Kuerer HM:, Con: Sentinel lymph node biopsy for DCIS. The breast surgeon is not a barber. Ann Surg Oncol 2007; 14: 1007-1008.
8. Meijnen P, Oldenburg HS, Loo CE, et al.: Risk of invasion and axillary lymph node metastasis in ductal carcinoma in situ diagnosed by core-needle biopsy. Br J Surg 2007; 94: 952-956.
9. Doyle B, Al-Mudhaffer M, Kennedy MM, et al.: Sentinel lymph node biopsy in patients with a needle core biopsy diagnosis of ductal carcinoma in situ: Is it justified ? J Clin Pathol 2009; 62: 534-538.
10. Goyal A, Douglas-Jones A, Monypenny I, et al.: Is there a role of sentinel lymph node biopsy in ductal carcinoma in situ?: Analysis of 587 cases. Breast Cancer Res Treat 2006; 98: 311-314.
11. van la Parra RF, Ernst MF, Barneveld PC, et al.: The value of sentinel lymph node biopsy in ductal carcinoma in situ (DCIS) and DCIS with microinvasion of the breast. Eur J Surg Oncol 2008; 34: 631-635.
12. Ansari B, Ogston SA, Purdie CA, et al.: Meta-analysis of sentinel node biopsy in ductal carcinoma in situ of the breast. Br J Surg 2008; 95: 547-554.
13. Feldman SM, Krag DN, McNally RK, et al.: Limitation in gamma probe localization of the sentinel node in breast cancer patients with large excisional biopsy. J Am Coll Surg 1999; 188: 248-254.
14. McLaughlin SA, Wright MJ, Morris KT, et al.: Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: Objective measurements. J Clin Oncol 2008; 26: 5213-5219.
15. Jackman RJ, Burbank F, Parker SH, et al.: Stereotactic breast biopsy of nonpalpable lesions: Determinants of ductal carcinoma in situ underestimation rates. Radiology 2001; 218: 497-502.
16. Wilkie C, White L, Dupont E, et al.: An update of sentinel lymph node mapping in patients with ductal carcinoma in situ. Am J Surg 2005; 190: 563-566.
17. Polom K, Murawa D, Wasiewicz J, et al.: The role of sentinel node biopsy in ductal carcinoma in situ of the breast. Eur J Surg Oncol 2009; 35: 43-47.
18. Suh YJ, Kim MJ, Kim EK, et al.: Comparison of the underestimation rate in cases with ductal carcinoma in situ at ultrasound-guided core biopsy: 14-gauge automated core-needle biopsy vs 8- or 11-gauge vacuum-assisted biopsy. Br J Radiol 2012; in press.
19. King TA, Farr GH Jr, Cederbom GJ, et al.: A mass on breast imaging predicts coexisting invasive carcinoma in patients with a core biopsy diagnosis of ductal carcinoma in situ. Am Surg 2001; 67: 907-912.
20. Lee JW, Han W, Ko E, et al.: Sonographic lesion size of ductal carcinoma in situ as a preoperative predictor for the presence of an invasive focus. J Surg Oncol 2008; 98: 15-20.
21. Kurniawan ED, Rose A, Mou A, et al.: Risk factors for invasive breast cancer when core needle biopsy shows ductal carcinoma in situ. Arch Surg 2010; 145: 1098-1104.
22. Brennan ME, Turner RM, Ciatto S, et al.: Ductal carcinoma in situ at core-needle biopsy: Meta-analysis of underestimation and predictors of invasive breast cancer. Radiology 2011; 260: 119-128.
23. El-Bastawissi AY, White E, Mandelson MT, Taplin S:, Variation in mammographic breast density by race. Ann Epidemiol 2001; 11: 257-263.